HCS Pharma était présent au Workshop OoC pour une création et une structuration de la filière, organisé par Biovalley à l’Institut Pierre-Gilles de Gennes (Paris). Nous sommes très heureux d’avoir pu sponsoriser l’événement, mais aussi tout simplement d’y avoir participé – en présentiel – et de pouvoir discuter avec des chercheurs Read more…
How to make in vitro models predictive of in vivo conditions? Dynamic models hold promise for future predictive microphysiological systems (MPS). By combining BIOMIMESYS® as an ECM surrogate for 3D culture, and hiPSC-derived cells, these dynamic microfluidic systems will revolutionize the field, reproducing human tissues and predict human outcomes.
On the occasion of the breast cancer awareness month, HCS Pharma is willing to thank all researchers working in the field to better understand the pathophysiology of disease, with the objective to find more efficient anti-cancer therapies. We would like to warmly thank the researchers with whom we are collaborating Read more…
It’s pleasure to welcome Thomas in our team. After a four-month internship at the CrCHUM (Centre de recherche du Centre Hospitalier de l’Université de Montréal, Canada) in the field of microfluidic personalized medicine for prostate cancer, he joined us in September for a six- months-internship, as part of his Master’s Read more…
We are happy to tell you that HCS Pharma, SMMiL-E team (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer, CNRS UMI-2820 LIMMS/IIS) and Institut d’Electronique, de Micro-Electronique et de Nanotechnologie (IEMN) have successfully applied to a LabCom grant (‘COMmon LABoratory’)! A LabCom aims at gathering two entities Read more…